this page only  
Join BIO  
Member Directory  
Contact BIO  

Biotechnology Industry Organization
BIO Membership
Home
About BIO
Conferences & Events
Past BIO Events
Industry Calendar
State/Int'l Calendar
Members.BIO.org
BIOtech NOW
BIO Bulletins
Suggestion Box
Membership Directory
BIO Videos
News, Media, Speeches, & Publications
BIO Blogs & Podcasts
National Issues
Health
Food & Agriculture
Industrial & Environmental
Bioethics
Intellectual Property
Regulatory
• Tax & Financial
State & Local Issues
State by State Initiatives
Letters, Testimony & Comments
Speeches & Publications
Industry At-a-Glance
Business & Finance
BIOtech NOW


Monday, March 22, 2010

Permanent Extension of the R&D Tax Credit

Click here for a printer-friendly page Printer Friendly

R&D Credit Coalition Logo

The Honorable Bill Thomas
Chairman
Committee on Ways and Means
United States House of Representatives
Washington, DC 20515
The Honorable Charles Rangel
Ranking Member
Committee on Ways and Means
United States House of Representatives
Washington, DC 20515
The Honorable Charles Grassley
Chairman
Committee on Finance
United States Senate
Washington, DC 20510
The Honorable Max Baucus
Ranking Member
Committee on Finance
United States Senate
Washington, DC 20510

Dear Chairman Thomas and Grassley, and Ranking Member Rangel and Baucus:

As Congress considers tax legislation that will stimulate growth in the economy, we urge you to include a permanent extension of the research and experimentation tax credit (the "R&D credit") with the modifications that are contained in H.R.463 and S.664. These changes will make the credit a more effective incentive for research-intensive businesses to perform R&D in the United States.

Research-intensive businesses are facing the same challenges as other companies in the U.S. After a decade of tremendous growth in R&D spending, current projections show flat growth in R&D spending for 2003. These projections are troublesome. Since the credit was created in 1981, investments in technology and innovation have spurred economic growth and contributed greatly to our country’s high standard of living. Continued R&D spending is a necessary element in our country’s ability to invest for our future.

The R&D tax credit provides companies with a critical, effective and proven incentive to maintain and increase their investment in U.S.-based research and development. Making the credit permanent will provide certainty to businesses that are making critical long-term investment decisions. A permanent credit will encourage the expedited initiation of research projects, create additional jobs and lay a foundation for long-term economic expansion in the U.S.

The credit also should be strengthened so that it provides an incentive for even more businesses engaged in significant research to invest in R&D in the United States. An increase in the Alternative Incremental Research Credit (AIRC) rates and a new elective alternative credit formula, as proposed in H.R.463 and S.664, would provide such an incentive.

Continued growth of our economy is inextricably tied to the ability of companies to make a sustained commitment to long-term research. We thank you for your dedication to policies that will strengthen our economy in this uncertain period and ask for your strong support for enacting a permanent and strengthened credit this year.

Sincerely,

contact us | terms of use | privacy policy
© 2009 | Biotechnology Industry Organization | 1201 Maryland Ave., SW, Ste. 900 | Washington, D.C. 20024